| Target Price | kr260.10 |
| Price | kr260.00 |
| Potential |
0.04%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Medistim 2026 .
The average Medistim target price is kr260.10.
This is
0.04%
register free of charge
kr325.50
25.19%
register free of charge
kr202.00
22.31%
register free of charge
|
|
| A rating was issued by 8 analysts: 6 Analysts recommend Medistim to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Medistim stock has an average upside potential 2026 of
0.04%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million kr | 562.60 | 655.86 |
| 6.89% | 16.58% | |
| EBITDA Margin | 27.66% | 29.24% |
| 6.15% | 5.73% | |
| Net Margin | 18.46% | 19.78% |
| 6.43% | 7.18% |
3 Analysts have issued a sales forecast Medistim 2025 . The average Medistim sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Medistim EBITDA forecast 2025. The average Medistim EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Medistim Analysts have issued a net profit forecast 2025. The average Medistim net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share kr | 5.67 | 7.10 |
| 0.00% | 25.22% | |
| P/E | 36.62 | |
| EV/Sales | 6.88 |
3 Analysts have issued a Medistim forecast for earnings per share. The average Medistim EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


